**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 84138

**Manuscript Type:** ORIGINAL ARTICLE

***Clinical Trials Study***

**Safety and effectiveness of vonoprazan-based rescue therapy for *Helicobacter pylori* infection**

Yu J *et al*. VPZ-based rescue regimen for *H. pylori*

Jing Yu, Yi-Ming Lv, Peng Yang, Yi-Zhou Jiang, Xiang-Rong Qin, Xiao-Yong Wang

**Jing Yu, Yi-Ming Lv, Peng Yang, Yi-Zhou Jiang, Xiang-Rong Qin, Xiao-Yong Wang,** Department of Gastroenterology, The Affiliated Changzhou No. 2 People’s Hospital of Nanjing Medical University, Changzhou 213000, Jiangsu Province, China

**Author contributions:** Wang XY contributed to conception and design of the study, critical revision, analysis and interpretation of data, drafting the article, revising the article; Yu J and Lv YM contributed to acquisition of data, analysis and interpretation of data, and drafting the article; Yang P, Jiang YZ, and Qin XR contributed to acquisition of data, analysis and interpretation of data; and all authors approved the final version of the manuscript.

**Supported by** the Changzhou Special Fund for Introducing Foreign Talents, No. CQ20204037; and the Changzhou High-Level Medical Talents Training Project, No. 2022CZBJ051.

**Corresponding author: Xiao-Yong Wang, MD, Assistant Professor, Chief Physician, Postdoc,** Department of Gastroenterology, The Affiliated Changzhou No. 2 People’s Hospital of Nanjing Medical University, No. 29 Xinglong Lane, Tianning District, Changzhou 213000, Jiangsu Province, China. wxy20009@126.com

**Received:** February 27, 2023

**Revised:** March 25, 2023

**Accepted:** April 23, 2023

**Published online:**

**Abstract**

BACKGROUND

Vonoprazan (VPZ)-based regimens are an effective first-line therapy for *Helicobacter pylori* (*H. pylori*) infection. However, their value as a rescue therapy needs to be explored.

AIM

To assess a VPZ-based regimen as *H. pylori* rescue therapy.

METHODS

This prospective, single-center, clinical trial was conducted between January and August 2022. Patients with a history of *H. pylori* treatment failure were administered 20 mg VPZ twice daily, 750 mg amoxicillin 3 times daily, and 250 mg *Saccharomyces boulardii* (*S. boulardii*) twice daily for 14 d (14-d VAS regimen). VPZ and *S. boulardii* were taken before meals, while amoxicillin was taken after meals. Within 3 d after the end of eradication therapy, all patients were asked to fill in a questionnaire to assess any adverse events they may have experienced. At least 4-6 wk after the end of eradication therapy, eradication success was assessed using a 13C-urea breath test, and factors associated with eradication success were explored.

RESULTS

Herein, 103 patients were assessed, and 68 patients were finally included. All included patients had 1-3 previous eradication failures. The overall eradication rates calculated using intention-to-treat and per-protocol analyses were 92.6% (63/68) and 92.3% (60/65), respectively. The eradication rate did not differ with the number of treatment failures (*P* = 0.433). The rates of clarithromycin, metronidazole, and levofloxacin resistance were 91.3% (21/23), 100.0% (23/23), and 60.9% (14/23), respectively. There were no cases of resistance to tetracycline, amoxicillin, or furazolidone. In 60.9% (14/23) patients, the *H. pylori* isolate was resistant to all 3 antibiotics (clarithromycin, metronidazole, and levofloxacin); however, eradication was achieved in 92.9% (13/14) patients. All patients showed metronidazole resistance, and had an eradication rate of 91.3% (21/23). The eradication rate was higher among patients without anxiety (96.8%) than among patients with anxiety (60.0%, *P* = 0.025). No severe adverse events occurred; most adverse events were mild and disappeared without intervention. Good compliance was seen in 95.6% (65/68) patients. Serological examination showed no significant changes in liver and kidney function.

CONCLUSION

VAS is a safe and effective rescue therapy, with an acceptable eradication rate (> 90%), regardless of the number of prior treatment failures. Anxiety may be associated with eradication failure.

**Key Words:** Vonoprazan; *Saccharomyces boulardii*; Rescue therapy*; Helicobacter pylori;* Eradication; Anxiety

Yu J, Lv YM, Yang P, Jiang YZ, Qin XR, Wang XY. Safety and effectiveness of vonoprazan-based rescue therapy for Helicobacter pylori infection. *World J Gastroenterol* 2023; In press

**Core Tip:** Vonoprazan (VPZ)-containing triple therapies have been shown to contribute to global antimicrobial resistance, while *Saccharomyces boulardii* (*S. boulardii*) supplementation has significantly improved *Helicobacter pylori* eradication rates and decreased adverse events. This study revealed that the VPZ and amoxicillin dual regimen with *S. boulardii* supplementation is safe and effective H. pylori rescue therapy, regardless of the number of prior treatment failures. Acceptable eradication rates (> 90%) were achieved in patients with resistance to clarithromycin, metronidazole, and levofloxacin. However, the regimen may need to be adjusted for patients with anxiety.

**INTRODUCTION**

*Helicobacter pylori* (*H. pylori*), which infects over 50% of the global population, is a leading cause of chronic gastritis, peptic ulcer disease, and gastric cancer. The eradication of *H. pylori* can effectively prevent peptic ulcer recurrence and lower gastric cancer incidence[1,2]. In regions with high antibiotic resistance, such as China, 14-d bismuth-containing quadruple therapy (BQT) is the recommended first-line treatment for *H. pylori* infection[3-5]. However, as the rates of resistance to clarithromycin, metronidazole, and levofloxacin have markedly increased worldwide, BQT fails to eradicate *H. pylori* infection in approximately 15%-20% patients[6,7]. Multiple failed attempts at eradication therapy tend to increase the prevalence of multidrug-resistant strains, making rescue treatment more difficult[8,9]. Unlike the above antibiotics, the rates of primary and secondary resistance of *H. pylori* to amoxicillin have remained low and stable[10]. Amoxicillin shows a pH- and time-dependent bactericidal effect. Recently, high-dose, high-frequency dual therapy with amoxicillin and a proton pump inhibitor (PPI) was reported to show promising outcomes when used as a first-line or rescue treatment for the eradication of *H. pylori*[11,12]. The Maastricht VI/Florence Consensus Report recommends high-dose dual therapy with a PPI plus amoxicillin as a rescue therapy for *H. pylori* infection[5].

Vonoprazan (VPZ), the first clinically available potassium-competing acid blocker (P-CAB), produces a more rapid and sustained acid inhibition effect than PPIs[13]. Therefore, VPZ-amoxicillin dual therapy (VA-dual) is expected to be more effective than PPI-amoxicillin dual therapy. In recent years, first-line treatment with VA-dual, consisting of amoxicillin (3 g/d or less) and VPZ (40 mg/d), has been reported to achieve eradication rates of 78.5%-93.5%[14-17]. However, limited reports are available on the success rate of VA-dual as a rescue treatment for *H. pylori* infection; only one retrospective study conducted in China has reported a successful eradication rate of 92.5% after VA-dual[18]. However, the regimens were not consistent, and the frequencies of the amoxicillin and VPZ doses varied. Therefore, further optimization of VA-dual as a rescue treatment is warranted.

Some recent consensus guidelines for the management of *H. pylori* infection have proposed that certain probiotics can effectively decrease the gastrointestinal side effects of *H. pylori* eradication therapies[3-5]. A recent meta-analysis demonstrated that *Saccharomyces boulardii* (*S. boulardii*) supplementation during standard eradication therapy (triple regimen, sequential regimen, or quadruple regimen) significantly improved eradication rates and decreased the overall incidence of adverse events[19]. However, few studies have evaluated the effects of *S. boulardii* as a supplement to the VA-dual regimen in terms of the eradication rate of *H. pylori* and treatment-related adverse events.

Therefore, the aim of this prospective study was to determine the safety and efficacy of VA-dual plus *S. boulardii* supplementation as a rescue treatment for patients with *H. pylori* infection. We additionally explored potential factors influencing eradication rates, and put forward our recommendations to improve *H. pylori* eradication rates in clinical practice.

**MATERIALS AND METHODS**

***Statement of ethics and trial registration***

Ethical approval for this pilot study was obtained from Affiliated Changzhou No. 2 People’s Hospital of Nanjing Medical University [No. (2021)YLJSD004]. The study adhered to the tenets of the Declaration of Helsinki. Written informed consent was obtained from all patients prior to their enrollment in this study. The study has been registered in the Chinese Clinical Trial Registry (No. ChiCTR2200055125).

***Study participants***

Patients who attended our center between January and August 2022 were screened for their eligibility to participate in this study. The detailed inclusion criteria were as follows: (1) Patients aged over 18 years; (2) patients with a history of at least one failed *H. pylori* eradication treatment; and (3) a minimum 6-mo interval after the end of the last treatment. The following exclusion criteria were applied: (1) A history of gastric surgery; (2) severe concomitant diseases such as hepatic or renal dysfunction; (3) allergy or contraindication to the drugs used in the study regimen; (4) pregnancy or lactation; (5) treatment with a PPI, bismuth, or an antibiotic within 4 wk before the study treatment; (6) alcohol abuse or drug addiction; and (7) lack of informed consent.

***Study design and outcomes***

Before enrollment, the patients’ demographic data, clinical characteristics, and any concomitant diseases were recorded through medical records and physician interviews. The diagnosis of *H. pylori* infection was based on a positive result of at least one of the following tests: 13C-urea breath test (13C-UBT), rapid urease test, and histological examination. Some patients also underwent gastroscopy, and *H. pylori* culture and antimicrobial susceptibility testing before treatment. Serum chemistry tests were performed before and after treatment.

All patients were administered VPZ (20 mg twice daily; Takeda Pharmaceutical, Tokyo, Japan), amoxicillin (750 mg 3 times daily; Federal Pharmaceutical, Hong Kong, China), and *S. boulardii* (250 mg twice daily; Laboratoires BIOCODEX, France) for 14 d (14-d VAS regimen). VPZ and *S. boulardii* were taken before meals, while amoxicillin was taken after meals. Patients who felt unwell during treatment or forgot to take their medication were advised to contact the investigators immediately.

All patients were asked to keep the remaining drugs after treatment and fill out the relevant questions in the questionnaire within 3 d after the end of eradication therapy. Adverse events and patient compliance were assessed using the questionnaires and the patients’ medication diaries. The intensity of the adverse events was graded as follows: None; mild, causing discomfort but not interfering with daily life; moderate, causing discomfort and interfering with daily life; and severe, causing discomfort requiring cessation of treatment. Patient compliance was rated as good if the patient had taken > 80% of all medications prescribed, and as poor, if not[20]. All patients underwent repeat 13C-UBT for the assessment of *H. pylori* infection 4-6 wk after the end of eradication therapy. The *H. pylori* status was interpreted as positive when the δ value was greater than the baseline value of 4, and as negative when the δ value was less than the baseline value of 4. If the δ value exceeded the baseline value, which was between 4 and 6, the test was repeated 1 mo later.

The primary endpoint of this study was the *H. pylori* eradication rate, as confirmed by a negative 13C-UBT. All patients were included in the intention-to-treat (ITT) analysis. Patients who did not undergo a 13C-UBT during follow-up were considered to have treatment failure in the ITT analysis. Patients who failed to attend follow-up assessments and those with poor compliance were excluded from the per protocol (PP) analysis. The secondary endpoints were the rate of adverse events, patient compliance, resistance to antibiotics, and factors related to the eradication rate.

***H. pylori culture and antimicrobial susceptibility testing***

From patients who underwent gastroscopy, we collected 2 biopsy specimens for *H. pylori* culture, one from the gastric antrum and another from the gastric corpus. Both specimens were stored at -80 °C in brain-heart infusion broth (Oxoid, Basingstoke, United Kingdom) and immediately transported to Zhiyuan Medical Laboratory Institute (Hangzhou, Zhejiang Province, China) for testing. Fully ground specimens were cultured and maintained for 3-7 d in brain-heart infusion agar medium (Oxoid, Basingstoke, United Kingdom) supplemented with 5% defibrinated sheep blood at 37 °C in a low-oxygen environment (85% N2, 10% CO2, and 5% O2). *H. pylori* isolates were identified on the basis of colony morphology and urease, catalase, and oxidase positivity.

The standard agar plate dilution method was used to assess *H. pylori* susceptibility to commonly used antibiotics. Minimum inhibitory concentrations (MICs) were calculated after 72 h of culture at 37 °C in a low-oxygen environment. We used *H. pylori* ATCC43504 (NCTC11637) for quality control. Antibiotic resistance was defined at the following MIC values: ≥ 1 µg/mL for clarithromycin, ≥ 8 µg/mL for metronidazole, and ≥ 2 µg/mL each for amoxicillin, furazolidone, levofloxacin, and tetracycline. The MIC values for antibiotic resistance were obtained from the fourth edition of the National Guide to Clinical Laboratory Procedures[21].

***Sample-size calculation and statistical analysis***

We assumed a 93% eradication rate with VPZ-based rescue therapy[22]. The 95% confidence interval was 86.6%-99.4%, and the sample size was 64 patients. Assuming a 5% follow-up loss, at least 68 patients would be required. Continuous variables were expressed as mean ± SD, and compared between groups by using the *t* test or Mann-Whitney *U* test. Categorical variables were expressed as numbers with percentages, and compared between groups by using the Fisher exact test or Pearson chi-square test. Statistical significance was inferred at *P* values < 0.05. All statistical analyses were conducted using Statistical Package for the Social Sciences *v*23.0 (IBM, Armonk, NY, United States) and Power Analysis and Sample Size software *v*15.0.5 (NCSS LLC, Kaysville, UT, United States).

**RESULTS**

***Patient characteristics***

We screened a total of 103 patients for eligibility, and excluded 35 patients who did not meet the inclusion criteria. Thus, finally, 68 patients were enrolled in this study, of whom 62 patients underwent endoscopy, 41 patients underwent serological testing before and after treatment, and 24 patients underwent antimicrobial susceptibility testing. Three patients were excluded from the PP analysis due to poor compliance despite a negative 13C-UBT during follow-up (Figure 1).

Of the 68 patients, 20 were men and 48 were women (Table 1). Prior to the present treatment, 47 patients had undergone treatment once, 15 patients had undergone treatment twice, and 6 patients had undergone treatment 3 times. Most patients were asymptomatic (*n* = 37, 54.4%). The most common concomitant diseases were hypertension (*n* = 14, 20.6%) and diabetes (*n* = 9, 13.2%); 4 patients (5.9%) had anxiety disorder. The most common previous treatment regimen was BQT, and the most commonly used antibiotics were amoxicillin, levofloxacin, clarithromycin, and metronidazole, with a few patients using furazolidone.

***H. pylori culture and antimicrobial susceptibility testing***

Of the 68 patients, 24 (35.3%) underwent *H. pylori* culture and antimicrobial susceptibility testing. *H. pylori* was successfully isolated in 95.8% (23/24) of patients. The rates of resistance to metronidazole, clarithromycin, and levofloxacin were 100% (23/23), 91.3% (21/23), and 60.0% (14/23), respectively. There were no cases of resistance to tetracycline, amoxicillin, or furazolidone. The triple drug-resistance rate (to metronidazole, levofloxacin, and clarithromycin) was 56.3% (9/16) among patients with one prior treatment failure, which increased to 71.4% (5/7) among patients with 2 or more prior treatment failures.

***Eradication rate and factors influencing efficacy***

The overall eradication rates of 14-d VAS calculated using the ITT and PP analyses were 92.6% (63/68) and 92.3% (60/65), respectively. In 2 of the 5 patients in whom eradication failed, further treatment with VPZ 20 mg twice daily, amoxicillin 1000 mg 3 times daily, and *S. boulardii* 250 mg twice daily for 14 d successfully eradicated the infection. The remaining 3 patients had not yet received additional rescue therapy at the time of writing as less than 6 mo had passed since the end of the previous treatment.

We stratified the *H. pylori* eradication rate by the number of prior treatment failures (Figure 2). The ITT analysis showed that the eradication rates were 93.6%, 93.3%, and 83.3% (*P* = 0.433) among patients with 1, 2, and 3 prior treatment failures, respectively. The corresponding eradication rates according to the PP analysis were 93.2%, 93.3%, and 83.3% (*P* = 0.585). We found that the eradication rate did not significantly differ with the number of previous treatment failures. In addition, eradication rates did not differ between patients who had previously received amoxicillin and those who had not (85.0% *vs* 95.8%, *P* = 0.433).

Among the 23 patients who successfully underwent *H. pylori* culture and antimicrobial susceptibility testing, the ITT analysis showed that similar eradication rates were achieved in the clarithromycin-resistant (90.4%) and clarithromycin-sensitive groups (100%; *P* = 1.00). PP analysis also showed that the eradication rate did not differ between the clarithromycin-resistant and clarithromycin-sensitive groups (90.0% *vs* 100%, respectively, *P* = 1.00). Similarly, we found no significant difference in the *H. pylori* eradication rate between the levofloxacin-resistant and levofloxacin-sensitive groups (ITT: 92.8% *vs* 88.8%, respectively, *P* = 1.00; PP: 92.3% *vs* 88.8%, respectively, *P* = 1.00; Figure 3). All patients showed metronidazole resistance, and had an eradication rate of 91.3% (21/23). Notably, eradication was achieved in92.9% (13/14) patients who showed triple drug resistance (clarithromycin, metronidazole, and levofloxacin).

Anxiety disorder was found to be a risk factor for eradication failure (40.0% *vs* 3.2%, *P* = 0.025; Table 2). No significant differences in age, sex, height, weight, body mass index, concomitant diseases, gastroscopy findings, and number of prior treatment failures were found between patients with successful and failed rescue therapy.

***Adverse events and compliance***

A total of 10 patients (14.7%) developed adverse events, including diarrhea (4 patients), skin rash (3 patients), and dry mouth, bloating, and abdominal pain (1 patient each). Most adverse events were mild and disappeared without intervention, except in 2 patients who developed rashes on day 9 and 11, refused continued rescue treatment, and finally recovered after anti-allergy therapy. Another patient discontinued treatment on day 7 because of diarrhea, which improved without intervention. The remaining patients took > 80% of all medications prescribed (compliance rate, 95.6%, 65/68; Table 3). Serum chemistry tests revealed no significant differences in liver and kidney function before and after treatment (Table 4). Among the 10 patients who developed adverse events, only 1 patient (with a rash) had eradication failure.

**DISCUSSION**

To our knowledge, this study is the first to determine the safety and efficacy of 14-d VA-dual plus *S. boulardii* supplementation as a rescue therapy for *H. pylori* infection. This VAS regimen achieved an acceptable eradication rate (92.6% by ITT and 92.3% by PP), regardless of the number of prior treatment failures. Most patients could tolerate this regimen, and compliance was good in this Chinese patient population. Except for anxiety disorder, no other factors were observed to be associated with treatment failure. Notably, eradication was successful in 92.9% (13/14) of patients with multiple antibiotic resistance. Therefore, the 14-d VAS regimen is a safe and effective rescue therapy for *H. pylori* infection.

Currently, *H. pylori* culture-guided therapy is recommended by most consensus guidelines as a rescue therapy for *H. pylori* infection. However, culture-guided therapy is not widely used in routine clinical practice[3-5]. Until recently, susceptibility tests still required the microbiological examination of samples obtained through endoscopy, which is invasive and expensive. In addition, many hospitals lack the facilities required to perform *H. pylori* culture and antimicrobial susceptibility testing, which limits the clinical use of culture-guided therapy in many countries[3,5,20]. Furthermore, *H. pylori* culture is technically challenging. Several studies have reported culture success rates of < 80% among patients with failure of at least one prior *H. pylori* eradication treatment[23]. It should be emphasized that in our study, culture was performed in only 35.3% of the patients. This reflects the current state of routine clinical practice in China. Culture-guided therapy has not yet become a routine clinical practice, and rescue therapy is mainly prescribed on an empirical basis in China.

Compared with PPIs, VPZ, the first clinically applied P-CAB, has a faster and stronger acid-inhibition effect[13]. This provides an opportunity to potentially improve *H. pylori* eradication therapy by simplifying complex regimens and possibly helping to develop effective therapies[5]. In one study, a PP analysis showed that a 7-d VPZ-based regimen (VPZ 20 mg twice daily, sitafloxacin 100 mg twice daily, and amoxicillin 750 mg twice daily) as a third-line therapy resulted in a significantly higher eradication rate than a PPI-based regimen (83.3% *vs* 57.1%, *P* = 0.043)[24]. In a small study, a 10-d triple therapy regimen consisting of VPZ 20 mg twice daily, rifabutin 150 mg twice daily, and amoxicillin 750 mg twice daily yielded a 100% eradication rate in 19 patients with ≥ 3 prior treatment attempts[25]. Similarly, in 57 patients administered a 7-d rifabutin-containing triple therapy regimen (VPZ 20 mg twice daily, amoxicillin 500 mg 4 times daily, and 150 mg rifabutin 150 mg once daily) as a third- or later-line *H. pylori* eradication regimen, the eradication rate was 91.2%[26]. It should be emphasized that all the above studies were conducted in Japan, and they all used triple regimens containing VPZ and amoxicillin. Although the use of 2 antibiotics may lead to higher eradication rates, this practice promotes the use of an unnecessary second antibiotic[27]. Hence, optimization of VPZ-based rescue therapy needs to be further explored. However, the relevant research in Chinais limited. Only one retrospective study has reported that the 14-d VA-dual regimen (VPZ 20 mg/d or 40 mg/d and amoxicillin 3000 mg/d) was safe and effective as a rescue therapy (92.5%, 172/186); however, the frequencies and doses of VA-dual therapy varied among the patients[18].

The 14-d VAS regimen used in this study offers certain advantages over previous rescue therapies. First, it minimizes the use of antibiotics, which is especially important in the light of the global increase in *H. pylori* antibiotic resistance. Indeed, VPZ-containing triple therapies have been shown to contribute to global antimicrobial resistance[27]. The 14-d VAS regimen eliminated the need for a second antibiotic while providing remarkable *H. pylori* eradication efficacy. Second, the optimal amoxicillin dose for dual therapy remains uncertain. Available evidence suggests that a dose of 2 g/d is insufficient, and 3 g or 2.25-3.00 g in split doses (every 6 h or 8 h) may be optimal[27]. Therefore, amoxicillin was administered at a dose of 750 mg 3 times daily in the 14-d VAS regimen. Third, for the first time, we supplemented *S. boulardii* to VA-dual as a rescue therapy for *H. pylori* eradication. Several potential mechanisms by which *S. boulardii* acts as an adjunct to *H. pylori* eradication therapy have been elucidated: (1) It inhibits the growth and proliferation of *H. pylori* by upregulating short-chain fatty acids and other antimicrobial substances[28]; (2) it expresses a neuraminidase that reduces the expression of α(2-3)-linked sialic acid on the epithelial cell surface, which prevents the adhesion of *H. pylori* to the duodenal epithelium[29]; and (3) it reduces the incidence of adverse events and indirectly improves patient compliance, thereby increasing the eradication rate of *H. pylori*[19].

Poor patient compliance is a main cause of treatment failure, and adverse events are a key factor affecting patient compliance[30]. Our 14-d VAS regimen was well tolerated, and all adverse events were mild or moderate, with diarrhea (5.9%) and rash (4.4%) being the most common. Patient compliance was also good, which may be attributable to the low rate of adverse events and the simplicity of the regimen.

We analyzed the factors potentially influencing the eradication rate of the 14-d VAS regimen. Only anxiety disorder was significantly associated with eradication failure; other factors such as gender, age, smoking, and alcohol consumption were not associated with treatment failure. There is evidence that state anxiety and trait anxiety are related to *H. pylori* infection. Anxiety appears to heighten the intensity and perception of gastrointestinal signals, which gives patients more reasons to worry about their health, leading to a higher anxiety response, and making patients more inclined to seek medical advice[31]. Thus, identifying patients with anxiety prior to the treatment of *H. pylori* infection and management by a professional team including a gastroenterologist and a psychologist to improve anxiety may be necessary to improve eradication rates and reduce the costs associated with frequent medical consultations.

This study has some limitations. First, it is impossible to compare the safety and effectiveness of the VA-dual regimen and the VAS regimen because this study is a single-arm pilot study. Large-scale, multicenter randomized controlled trials in areas with different patterns of antibiotic resistance are needed to confirm our results. Second, the number of patients with anxiety disorder in this study was small, and the relevant conclusions and potential mechanisms need to be further explored in future studies. Third, *H. pylori* culture and antimicrobial susceptibility testing were performed in only 35.3% of our patients, and no resistance was detected to amoxicillin. So, it was impossible to determine whether amoxicillin resistance affected the eradication rate of the 14-d VAS regimen. However, considering that the rates of primary and secondary resistance to amoxicillin are low and stable[10], we believe that the 14-d VAS regimen is an effective rescue therapy. Fourth, this study was underpowered to analyze the association between eradication rate and prior eradication regimens because the study patients had previously been treated with multiple different regimens.

**CONCLUSION**

In conclusion, the 14-d VAS regimen is safe and effective *H. pylori* rescue therapy, with an acceptable eradication rate (> 90%), regardless of the number of prior treatment failures. This regimen avoids the use of additional antibiotics, but may need to be adjusted for patients with anxiety. Large-scale, multicenter randomized controlled trials are needed to confirm our results.

**ARTICLE HIGHLIGHTS**

***Research background***

Vonoprazan (VPZ)-containing triple therapies have been shown to contribute to global antimicrobial resistance. Hence, the value of VPZ-based regimens as rescue therapies needs to be explored.

***Research motivation***

*Saccharomyces boulardii* (*S. boulardii*) supplementation significantly improved *H. pylori* eradication rates and decreased the incidence of adverse events. We are the first to combine *S. boulardii* supplementation with VPZ-amoxicillin dual therapy (VAS regimen) as a rescue therapy for *H. pylori* eradication.

***Research objectives***

To determine the safety and efficacy of the VAS regimen as a rescue treatment for *H. pylori* infection.

***Research methods***

We performed a prospective, single-center, clinical trial with the VAS regimen.

***Research results***

The overall eradication rates calculated using intention-to-treat and per-protocol analyses were 92.6% and 92.3%, respectively. The eradication rate did not differ with the number of treatment failures (*P* = 0.433). Acceptable eradication rates (> 90%) were achieved in patients with resistance to clarithromycin, metronidazole, and levofloxacin. Most adverse events were mild, and 95.6% patients showed good compliance.

***Research conclusions***

The VAS regimen is a safe and effective rescue therapy, with an acceptable eradication rate (> 90%), regardless of the number of prior treatment failures.

***Research perspectives***

Large-scale, multicenter randomized controlled trials in areas with different patterns of antibiotic resistance are needed to confirm our results. It will be necessary to compare the safety and effectiveness of the VPZ-amoxicillin dual therapy regimen with the VAS regimen in the future.

**ACKNOWLEDGEMENTS**

The authors are grateful to Dr. Liu-Lan Qian for her help in the statistical analysis of this paper.

**REFERENCES**

1 **Zamani M**, Ebrahimtabar F, Zamani V, Miller WH, Alizadeh-Navaei R, Shokri-Shirvani J, Derakhshan MH. Systematic review with meta-analysis: the worldwide prevalence of Helicobacter pylori infection. *Aliment Pharmacol Ther* 2018; **47**: 868-876 [PMID: 29430669 DOI: 10.1111/apt.14561]

2 **Chiang TH**, Chang WJ, Chen SL, Yen AM, Fann JC, Chiu SY, Chen YR, Chuang SL, Shieh CF, Liu CY, Chiu HM, Chiang H, Shun CT, Lin MW, Wu MS, Lin JT, Chan CC, Graham DY, Chen HH, Lee YC. Mass eradication of Helicobacter pylori to reduce gastric cancer incidence and mortality: a long-term cohort study on Matsu Islands. *Gut* 2021; **70**: 243-250 [PMID: 32792335 DOI: 10.1136/gutjnl-2020-322200]

3 **Liu WZ**, Xie Y, Lu H, Cheng H, Zeng ZR, Zhou LY, Chen Y, Wang JB, Du YQ, Lu NH; Chinese Society of Gastroenterology, Chinese Study Group on Helicobacter pylori and Peptic Ulcer. Fifth Chinese National Consensus Report on the management of Helicobacter pylori infection. *Helicobacter* 2018; **23**: e12475 [PMID: 29512258 DOI: 10.1111/hel.12475]

4 **Chey WD**, Leontiadis GI, Howden CW, Moss SF. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. *Am J Gastroenterol* 2017; **112**: 212-239 [PMID: 28071659 DOI: 10.1038/ajg.2016.563]

5 **Malfertheiner P**, Megraud F, Rokkas T, Gisbert JP, Liou JM, Schulz C, Gasbarrini A, Hunt RH, Leja M, O’Morain C, Rugge M, Suerbaum S, Tilg H, Sugano K, El-Omar EM; European Helicobacter and Microbiota Study group. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. *Gut* 2022 [PMID: 35944925 DOI: 10.1136/gutjnl-2022-327745]

6 **Koroglu M**, Ayvaz MA, Ozturk MA. The efficacy of bismuth quadruple therapy, sequential therapy, and hybrid therapy as a first-line regimen for Helicobacter pylori infection compared with standard triple therapy. *Niger J Clin Pract* 2022; **25**: 1535-1541 [PMID: 36149216 DOI: 10.4103/njcp.njcp\_89\_22]

7 **Song Z**, Suo B, Zhang L, Zhou L. Rabeprazole, Minocycline, Amoxicillin, and Bismuth as First-Line and Second-Line Regimens for Helicobacter pylori Eradication. *Helicobacter* 2016; **21**: 462-470 [PMID: 27060292 DOI: 10.1111/hel.12313]

8 **Cortés P**, Nelson AD, Bi Y, Stancampiano FF, Murray LP, Pujalte GGA, Gomez V, Harris DM. Treatment Approach of Refractory Helicobacter pylori Infection: A Comprehensive Review. *J Prim Care Community Health* 2021; **12**: 21501327211014087 [PMID: 33949229 DOI: 10.1177/21501327211014087]

9 **Graham DY**, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. *Gut* 2010; **59**: 1143-1153 [PMID: 20525969 DOI: 10.1136/gut.2009.192757]

10 **Li SY**, Li J, Dong XH, Teng GG, Zhang W, Cheng H, Gao W, Dai Y, Zhang XH, Wang WH. The effect of previous eradication failure on antibiotic resistance of Helicobacter pylori: A retrospective study over 8 years in Beijing. *Helicobacter* 2021; **26**: e12804 [PMID: 33860967 DOI: 10.1111/hel.12804]

11 **Bi H**, Chen X, Chen Y, Zhao X, Wang S, Wang J, Lyu T, Han S, Lin T, Li M, Yuan D, Liu J, Shi Y. Efficacy and safety of high-dose esomeprazole-amoxicillin dual therapy for Helicobacter pylori rescue treatment: a multicenter, prospective, randomized, controlled trial. *Chin Med J (Engl)* 2022; **135**: 1707-1715 [PMID: 36193978 DOI: 10.1097/CM9.0000000000002289]

12 **Guan JL**, Hu YL, An P, He Q, Long H, Zhou L, Chen ZF, Xiong JG, Wu SS, Ding XW, Luo HS, Li PY. Comparison of high-dose dual therapy with bismuth-containing quadruple therapy in Helicobacter pylori-infected treatment-naive patients: An open-label, multicenter, randomized controlled trial. *Pharmacotherapy* 2022; **42**: 224-232 [PMID: 35075679 DOI: 10.1002/phar.2662]

13 **Sakurai Y**, Mori Y, Okamoto H, Nishimura A, Komura E, Araki T, Shiramoto M. Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects--a randomised open-label cross-over study. *Aliment Pharmacol Ther* 2015; **42**: 719-730 [PMID: 26193978 DOI: 10.1111/apt.13325]

14 **Zuberi BF**, Ali FS, Rasheed T, Bader N, Hussain SM, Saleem A. Comparison of Vonoprazan and Amoxicillin Dual Therapy with Standard Triple Therapy with Proton Pump Inhibitor for Helicobacter Pylori eradication: A Randomized Control Trial. *Pak J Med Sci* 2022; **38**: 965-969 [PMID: 35634610 DOI: 10.12669/pjms.38.4.5436]

15 **Chey WD**, Mégraud F, Laine L, López LJ, Hunt BJ, Howden CW. Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the United States and Europe: Randomized Clinical Trial. *Gastroenterology* 2022; **163**: 608-619 [PMID: 35679950 DOI: 10.1053/j.gastro.2022.05.055]

16 **Suzuki S**, Gotoda T, Kusano C, Ikehara H, Ichijima R, Ohyauchi M, Ito H, Kawamura M, Ogata Y, Ohtaka M, Nakahara M, Kawabe K. Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: a multicentre randomised trial in Japan. *Gut* 2020; **69**: 1019-1026 [PMID: 31915235 DOI: 10.1136/gutjnl-2019-319954]

17 **Gotoda T**, Kusano C, Suzuki S, Horii T, Ichijima R, Ikehara H. Clinical impact of vonoprazan-based dual therapy with amoxicillin for H. pylori infection in a treatment-naïve cohort of junior high school students in Japan. *J Gastroenterol* 2020; **55**: 969-976 [PMID: 32666199 DOI: 10.1007/s00535-020-01709-4]

18 **Gao W**, Teng G, Wang C, Xu Y, Li Y, Cheng H. Eradication rate and safety of a "simplified rescue therapy": 14-day vonoprazan and amoxicillin dual regimen as rescue therapy on treatment of Helicobacter pylori infection previously failed in eradication: A real-world, retrospective clinical study in China. *Helicobacter* 2022; **27**: e12918 [PMID: 35877765 DOI: 10.1111/hel.12918]

19 **Zhou BG**, Chen LX, Li B, Wan LY, Ai YW. Saccharomyces boulardii as an adjuvant therapy for Helicobacter pylori eradication: A systematic review and meta-analysis with trial sequential analysis. *Helicobacter* 2019; **24**: e12651 [PMID: 31414551 DOI: 10.1111/hel.12651]

20 **Wang JW**, Hsu PI, Lin MH, Kao J, Tsay FW, Wu IT, Shie CB, Wu DC. The efficacy of culture-guided *versus* empirical therapy with high-dose proton pump inhibitor as third-line treatment of Helicobacter pylori infection: A real-world clinical experience. *J Gastroenterol Hepatol* 2022; **37**: 1928-1934 [PMID: 35816187 DOI: 10.1111/jgh.15942]

21 **Shang H**, Wang YS, Shen ZY. National Guide to Clinical Laboratory Procedures. 4th ed. Beijing: People’s medical Publishing House, 2014: 574-628

22 **Saito Y**, Konno K, Sato M, Nakano M, Kato Y, Saito H, Serizawa H. Vonoprazan-Based Third-Line Therapy Has a Higher Eradication Rate against Sitafloxacin-Resistant Helicobacter pylori. *Cancers (Basel)* 2019; **11** [PMID: 30669474 DOI: 10.3390/cancers11010116]

23 **Gisbert JP**. Empirical or susceptibility-guided treatment for Helicobacter pylori infection? A comprehensive review. *Therap Adv Gastroenterol* 2020; **13**: 1756284820968736 [PMID: 33240392 DOI: 10.1177/1756284820968736]

24 **Sue S**, Shibata W, Sasaki T, Kaneko H, Irie K, Kondo M, Maeda S. Randomized trial of vonoprazan-based *versus* proton-pump inhibitor-based third-line triple therapy with sitafloxacin for Helicobacter pylori. *J Gastroenterol Hepatol* 2019; **34**: 686-692 [PMID: 30151994 DOI: 10.1111/jgh.14456]

25 **Hirata Y**, Yamada A, Niikura R, Shichijo S, Hayakawa Y, Koike K. Efficacy and safety of a new rifabutin-based triple therapy with vonoprazan for refractory Helicobacter pylori infection: A prospective single-arm study. *Helicobacter* 2020; **25**: e12719 [PMID: 32602161 DOI: 10.1111/hel.12719]

26 **Inokuchi K**, Mori H, Matsuzaki J, Hirata K, Harada Y, Saito Y, Suzuki H, Kanai T, Masaoka T. Efficacy and safety of low-dose rifabutin-based 7-day triple therapy as a third- or later-line Helicobacter pylori eradication regimen. *Helicobacter* 2022; **27**: e12900 [PMID: 35644041 DOI: 10.1111/hel.12900]

27 **Graham DY**, Lu H, Shiotani A. Vonoprazan-containing Helicobacter pylori triple therapies contribution to global antimicrobial resistance. *J Gastroenterol Hepatol* 2021; **36**: 1159-1163 [PMID: 32918832 DOI: 10.1111/jgh.15252]

28 **McFarland LV**. Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. *World J Gastroenterol* 2010; **16**: 2202-2222 [PMID: 20458757 DOI: 10.3748/wjg.v16.i18.2202]

29 **Sakarya S**, Gunay N. Saccharomyces boulardii expresses neuraminidase activity selective for α2,3-linked sialic acid that decreases Helicobacter pylori adhesion to host cells. *APMIS* 2014; **122**: 941-950 [PMID: 24628732 DOI: 10.1111/apm.12237]

30 **Li H**, Liang X, Chen Q, Zhang W, Lu H. Inappropriate treatment in Helicobacter pylori eradication failure: a retrospective study. *Scand J Gastroenterol* 2018; **53**: 130-133 [PMID: 29214879 DOI: 10.1080/00365521.2017.1413132]

31 **Addolorato G**, Mirijello A, D’Angelo C, Leggio L, Ferrulli A, Abenavoli L, Vonghia L, Cardone S, Leso V, Cossari A, Capristo E, Gasbarrini G. State and trait anxiety and depression in patients affected by gastrointestinal diseases: psychometric evaluation of 1641 patients referred to an internal medicine outpatient setting. *Int J Clin Pract* 2008; **62**: 1063-1069 [PMID: 18422970 DOI: 10.1111/j.1742-1241.2008.01763.x]

**Footnotes**

**Institutional review board statement:** The study was reviewed and approved by the Clinical Medical Technical Ethics Committee of the Affiliated Changzhou No. 2 People’s Hospital of Nanjing Medical University [approval. No. (2021) YLJSD004].

**Clinical trial registration statement:** This study is registered at Chinese Clinical trial Registry. The registration identification number is ChiCTR2200055125.

**Informed consent statement:** All study participants provided informed written consent prior to the study enrollment and declare that they have no conflict of interest.

**Conflict-of-interest statement:** The authors declare that they have no conflict of interest.

**Data sharing statement:** The data that support the findings of this study are available from the corresponding author upon reasonable request.

**CONSORT 2010 statement:** The authors have read the CONSORT 2010 statement, and the manuscript was prepared and revised according to the CONSORT 2010 statement.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** February 27, 2023

**First decision:** March 13, 2023

**Article in press:**

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0


Grade C (Good): C, C, C

Grade D (Fair): 0


Grade E (Poor): 0

**P-Reviewer:** Keikha M, Iran; Krzyzek P, Poland; Nishida T, Japan **S-Editor:** Chen YL **L-Editor:** A **P-Editor:**


**Figure Legends**



**Figure 1 Flow chart of the study.** PPI: Proton pump inhibitor; ITT: Intention-to-treat analysis; PP: Per-protocol analysis; UBT: Urea breath test; *H. pylori*: *Helicobacter pylori*.



**Figure 2 Eradication rates stratified by number of prior treatment failures.** ITT: 93.6% *vs* 93.3% *vs* 83.3%, *P* = 0.433; PP: 93.2% *vs* 93.3% *vs* 83.3%, *P* = 0.585). ITT: Intention-to-treat analysis; PP: Per-protocol analysis.



**Figure 3 Impact of bacterial antibiotic resistance on eradication rate.** ITT: Clarithromycin resistant *vs* clarithromycin sensitive, *P* = 1.00; levofloxacin resistant *vs* levofloxacin sensitive, *P* = 1.00; PP: Clarithromycin resistant *vs* clarithromycin sensitive, *P* = 1.00; levofloxacin resistant *vs* levofloxacin sensitive, *P* = 1.00). R-CLA: Clarithromycin resistant; S-CLA: Clarithromycin sensitive; R-LEV: Levofloxacin resistant; S-LEV: Levofloxacin sensitive; ITT: Intention-to-treat analysis; PP: Per-protocol analysis.

**Table 1** **Clinicodemographic characteristics of the study patients, *n* (%)**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Characteristic** | **Total No. of patients (*n* = 68)** | **Number of prior eradication failures** | | |
| **1 (*n* = 47)** | **2 (*n* = 15)** | **3 (*n* = 6)** |
| Sex (male) | 20 (29.4) | 10 (21.3) | 6 (4.0) | 4 (66.7) |
| Age (yr), mean ± SD | 49.60 ± 10.57 | 49.94 ± 10.00 | 48.87 ± 12.65 | 48.83 ± 11.27 |
| Height (m), mean ± SD | 1.63 ± 0.07 | 1.62 ± 0.09 | 1.64 ± 0.08 | 1.68 ± 0.10 |
| Weight (kg), mean ± SD | 59.52 ± 12.30 | 56.83 ± 12.19 | 63.80 ± 9.94 | 69.92 ± 11.50 |
| BMI (kg/m2), mean ± SD | 22.31 ± 3.64 | 21.59 ± 3.98 | 23.63 ± 2.04 | 24.63 ± 1.80 |
| Lifestyle factors | | | | |
| Smoking | 5 (7.3) | 4 (8.5) | 0 (0) | 1 (16.7) |
| Drinking | 4 (5.9) | 0 (0) | 1 (6.7) | 3 (50.0) |
| Symptom | |  |  |  |
| Abdominal pain | 7 (10.3) | 5 (10.6) | 2 (13.3) | 0 (0) |
| Bloating | 6 (8.8) | 4 (8.5) | 2 (13.3) | 0 (0) |
| Diarrhea | 1 (1.5) | 0 (0) | 1 (6.7) | 0 (0) |
| Halitosis | 1 (1.5) | 1 (2.1) | 0 (0) | 0 (0) |
| Belching | 13 (19.1) | 8 (17.0) | 3 (20.0) | 2 (33.4) |
| Nausea | 2 (2.9) | 2 (4.3) | 0 (0) | 0 (0) |
| Bitter taste | 1 (1.5) | 1 (2.1) | 0 (0) | 0 (0) |
| Asymptomatic | 37 (54.4) | 26 (55.3) | 7 (46.7) | 4 (66.7) |
| Concomitant disease | |  |  |  |
| Diabetes mellitus | 9 (13.2) | 8 (17.0) | 1 (6.7) | 0 (0) |
| Hypertension | 14 (20.6) | 7 (14.9) | 5 (33.3) | 2 (33.4) |
| Anxiety disorder | 4 (5.9) | 1 (2.1) | 2 (13.3) | 1 (16.7) |
| Gastroscopy findings | | | | |
| Atrophic gastritis | 33 (48.6) | 27 (57.4) | 4 (26.7) | 2 (33.4) |
| Non-atrophic gastritis | 24 (35.3) | 14 (29.8) | 8 (53.3) | 2 (33.4) |
| Peptic ulcer | 4 (5.9) | 1 (2.1) | 1 (6.7) | 2 (33.4) |
| Polyp | 1 (1.5) | 0 (0) | 1 (6.7) | 0 (0) |
| Not applicable (no gastroscopy done) | 6 (8.9) | 5 (10.6) | 1 (13.3) | 0 (0) |

BMI: Body mass index.

**Table 2 Factors potentially influencing *Helicobacter pylori* eradication, *n* (%)**

|  |  |  |  |
| --- | --- | --- | --- |
| **Factor** | **Eradication failure (*n* = 5)** | **Successful eradication (*n* = 63)** | ***P* value** |
| Sex (male) | 2 (40.0) | 18 (28.6) | 0.627 |
| Age (yr), mean ± SD | 54.40 ± 5.86 | 49.22 ± 10.80 | 0.295 |
| Height (m), mean ± SD | 1.62 ± 0.10 | 1.62 ± 0.07 | 0.778 |
| Weight (kg), mean ± SD | 64.60 ±11.42 | 59.12 ± 12.37 | 0.129 |
| BMI (kg/m2), mean ± SD | 24.43 ± 1.88 | 22.14 ± 3.70 | 0.112 |
| Concomitant disease | | | |
| Diabetes mellitus | 1 (20.0) | 8 (12.7) | 0.520 |
| Hypertension | 1 (20.0) | 13 (20.6) | 1.000 |
| Anxiety disorder | 2 (40.0) | 2 (3.2) | 0.025 |
| Gastroscopy findings | | | |
| Atrophic gastritis | 2 (40.0) | 31 (49.2) | 1.000 |
| Non-atrophic gastritis | 3 (60.0) | 21 (33.3) | 0.337 |
| Peptic ulcer | 0 (0.0) | 4 (6.3) | 1.000 |
| Polyp | 0 (0.0) | 1 (1.6) | 1.000 |
| No. of prior treatments | | | |
| 1 | 3 (60.0) | 44 (69.8) | 0.641 |
| ≥ 2 | 2 (40.0) | 19 (30.2) |  |

BMI: body mass index.

**Table 3 Adverse events and patient compliance**

|  |  |
| --- | --- |
| **Variable** | **%** |
| Adverse events |  |
| Total adverse events | 14.7% (10/68) |
| Dry mouth | 1.5% (1/68) |
| Skin rash | 4.4% (3/68) |
| Bloating | 1.5% (1/68) |
| Diarrhea | 5.9% (4/68) |
| Abdominal pain | 1.5% (1/68) |
| Grade of adverse event |  |
| Mild | 70.0% (7/10) |
| Moderate | 30.0% (3/10) |
| Severe | 0% (0/10) |
| 1Compliance |  |
| Good | 95.6% (65/68) |
| Poor | 4.4% (3/68) |

1Compliance was rated as good if the patient had taken > 80% of all medications prescribed, and as poor, if not.

**Table 4 Comparison of liver and kidney function before and after treatment**

|  |  |  |  |
| --- | --- | --- | --- |
| **Characteristic** | **Before (*n* = 41)** | **After (*n* = 41)** | ***P* value** |
| Total bilirubin (μmol/L), mean ± SD | 13.68 ± 4.82 | 14.96 ± 5.22 | 0.252 |
| ALT (U/L), mean ± SD | 16.92 ± 8.33 | 21.46 ± 16.03 | 0.270 |
| AST (U/L), mean ± SD | 18.99 ± 7.61 | 21.03 ± 10.67 | 0.670 |
| Creatinine (μmol/L), mean ± SD | 60.105 ± 12.060 | 60.53 ± 11.35 | 0.974 |

AST: Aspartate transaminase; ALT: Alanine transaminase.